Autolus Therapeutics (AUTL) Cash & Current Investments (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Cash & Current Investments for 9 consecutive years, with $300.7 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Current Investments fell 48.86% year-over-year to $300.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $300.7 million (down 48.86% YoY) and the FY2025 annual result came in at $300.7 million, down 48.86% from the prior year.
• Cash & Current Investments declined to $300.7 million in Q4 2025 per AUTL's latest filing, from $367.4 million in the prior quarter.
• Over the last five years, Cash & Current Investments for AUTL reached as high as $759.5 million in Q1 2024 and fell as low as $163.4 million in Q3 2022.
• A 5-year average of $373.6 million and a median of $309.3 million in 2021 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments surged 39426.21% — and 2025, when it sank 48.86%.
• Year by year, Cash & Current Investments stood at $310.7 million in 2021, then advanced by 23.2% to $382.8 million in 2022, then slumped by 37.21% to $240.3 million in 2023, then soared by 144.67% to $588.0 million in 2024, then plunged by 48.86% to $300.7 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $300.7 million, $367.4 million, and $454.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.